A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification - Archive ouverte HAL Access content directly
Journal Articles Seminars in Oncology Year : 2017

A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification

(1, 2) , (3) , (1, 2) , (4) , (5) , (6) , (7) , (8) , (9) , (2, 1) , (1, 2) , (1, 2) , (1, 2)
1
2
3
4
5
6
7
8
9
Thierry Lecomte
  • Function : Author
  • PersonId : 859599

Abstract

We conducted a multicenter proof of concept phase II trial in patients with advanced colorectal cancer receiving FOLFIRI-cetuximab regimens to explore individual drug tailoring using pharmacogenetics and pharmacokinetics (PK) monitoring. Patients were stratified by their pharmacogenetic/phenotypic status: the irinotecan dose was adjusted according to the number of TA tandem repeats in the UGT1A1 promoter, while the 5-fluorouracil (5-FU) dose was initially adjusted according to dihydropyrimidine dehydrogenase (DPD) activity at initial screening (5-FU[ODPM Tox]) followed by PK-guided dose optimization (5-FU[ODPM Protocol]). An advanced cetuximab PK/pharmacodynamics (PD) study was performed but dosage remained unchanged. Eighty-five patients receiving second-line chemotherapy were enrolled. Mean irinotecan doses at 3 months were 247 ± 50, 210 ± 53 and 140 ± 21 mg/m[2] for those with 6/6 (33), 6/7 (26), and 7/7 (7) TATA repeats in the UGT1A1 promoter region, respectively. The 5-FU dose was initially reduced in four patients with DPD deficiency, but mean 5-FU dose at 3 months was 2,412 ± 364 mg/m2 (1,615-3,170 mg/m[2]). Grade 4 toxicities were not encountered and grade 4 neutropenia occurred in 6.8%, 5.9%, and 0% of patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes. The objective response rate was 25.8% among the 85 patients, 57.3% in patients with tumors wild type (WT) for KRAS, and 25% in those whose tumor harbored a mutant-KRAS. Secondary resection of hepatic metastases was performed in 31.7% of patients. Median progression-free survival (PFS) for all 85 patients was 181 days and 200, 132, and 121 days for patients with 6/6, 6/7, and 7/7 UGT1A1 genotypes, respectively; these differences were not statistically different. In parallel, a strong relationship was shown between cetuximab AUC and regimen efficacy. We conclude that personalized drug tailoring when administering in FOLFIRI + cetuximab allows for safe and efficient individual dose intensification.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01819425 , version 1 (20-06-2018)

Identifiers

Cite

Michele Boisdron-Celle, Jean Philippe Metges, Olivier Capitain, Antoine Adenis, Jean Luc Raoul, et al.. A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification. Seminars in Oncology, 2017, 44 (1), pp.24 - 33. ⟨10.1053/j.seminoncol.2017.02.007⟩. ⟨inserm-01819425⟩
144 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More